Prostate cancer is the most frequently diagnosed male cancer, and its clinical outcome is difficult to predict. The disease may involve the inappropriate expression of genes that normally control the proliferation of epithelial cells in the basal layer and their differentiation into luminal cells. Our aim was to identify novel basal cell markers and assess their prognostic and functional significance in prostate cancer. RNA from basal and luminal cells isolated from benign tissue by immunoguided laser-capture microdissection was subjected to expression profiling. We identified 112 and 267 genes defining basal and luminal populations, respectively. The transcription factor TEAD1 and the ubiquitin ligase c-Cbl were identified as novel basal cell markers. Knockdown of either marker using siRNA in prostate cell lines led to decreased cell growth in PC3 and disrupted acinar formation in a 3D culture system of RWPE1. Analyses of prostate cancer tissue microarray staining established that increased protein levels of either marker were associated with decreased patient survival independent of other clinicopathological metrics. These data are consistent with basal features impacting on the development and clinical course of prostate cancers.
Prostate cancer is one of the most common malignancies in the western world, but markers that accurately predict the highly variable course of the disease are lacking.
Normal prostate tissue consists of glands containing two well-defined epithelial layers surrounding a central lumen. The outer basal layer is the site of proliferation (Hudson et al, 2001) and the inner layer is made up of secretory luminal cells arising from the basal layer through differentiation (Signoretti et al, 2005). Changes in the balance between epithelial cell division and differentiation may play a key role in the development of both prostate cancer and benign prostatic hyperplasia (BPH) (Bonkhoff and Remberger, 1996). Prostate cancer cells resemble those of the luminal layer (Browne et al, 2004), particularly in their expression of prostate-specific antigen (PSA) and the androgen receptor (AR). Unlike luminal cells, however, and in common with basal cells, cancer cells maintain the ability to proliferate. Although a defining feature of prostate cancer is the complete loss of the basal cell layer, there is evidence for a maintained expression of genes normally restricted to basal cells, including MET (Pisters et al, 1995), BCL-2 (McDonnell et al, 1992), SOX9 (Wang et al, 2007), KLK4 (Klokk et al, 2007) and S100A9 (Hermani et al, 2005). Furthermore, the cancer-initiating cell is widely believed to be of basal origin (Bui and Reiter, 1998), expressing known basal markers including keratin (K)14, α2β1 integrin and CD44 (Collins et al, 2005; Patrawala et al, 2007). We therefore hypothesised that basal cell features are of key importance in the development of prostate tumours.
To address this, we used immunoguided laser-capture microdissection to isolate prostate basal and luminal epithelial cells under conditions that preserve RNA of sufficient quality for expression profiling. This identified gene expression patterns relating to proliferation and differentiation within benign prostate epithelium. TEAD1 (a transcription factor) and c-Cbl (an E3 ubiquitin ligase) were confirmed as novel basal cell markers. Analysis of their expression across a range of prostate cancer samples on tissue microarrays (TMAs) demonstrated each to have a prognostic value. Finally, the functional significance of TEAD1 and c-Cbl in controlling growth and differentiation of prostate cell lines was examined using RNA interference.
Materials and methods
Frozen tissue was obtained from five consented patients undergoing transurethral resection of the prostate for BPH.
The TMA consisted of 774 formalin-fixed paraffin-embedded cores representing benign epithelium (43 patients), hyperplastic epithelium (124 patients) and prostate cancer (147 patients) (Foster et al, 2004). The prostate cancer samples were from consecutive patients attending the Royal Marsden NHS Trust from 1992 with follow-up times of up to 16.6 years (median 6.9 years). Owing to the long follow-up period for this patient set, PSA values were unavailable for many patients.
Immunohistochemistry and laser microdissection pressure catapulting
Basal cells were distinguished by immunostaining for K14 (Abd Serotec, Kidlington, UK). Primary and secondary antibodies were used at 1 : 25 and 1 : 100 dilutions, respectively, allowing 5-min incubations. Antibodies were visualised using the Vectastain Elite ABC kit and chromogen 3,3′-diaminobenzidine (DAB; Vector Laboratories Ltd, Peterborough, UK) with incubations of 5 and 2 min, respectively, and a 7 s haematoxylin counterstain. Sections were rapidly dehydrated through graded alcohols and then air-dried for 5 min. RNase inhibitor (Roche Diagnostics Ltd, Burgess Hill, UK) was used at a concentration of 0.5 U μl−1 in all solutions.
Microdissection was performed using the PALM Microbeam (PALM Microlaser Technologies GmbH, Bernried, Germany) using the ‘close-cut autoLPC’ function. Capture buffer consisted of 0.5% Igepal (Sigma-Aldrich, Poole, UK) in HPLC water with RNase inhibitor. A total of 100–500 cells were captured from each section and cells from two adjacent sections were pooled.
RNA extraction and amplification
The Picopure RNA extraction kit (Molecular Devices Ltd, Wokingham, UK) was used according to the manufacturer's protocol. RNA was amplified through two rounds using the ExpressArt Trinucleotide Amplification Nano Kit for degraded RNA (Amp Tec GmbH, Hamburg, Germany). Amplified RNA quality was assessed using the Agilent 2100 Bioanalyser (Agilent Technologies UK Ltd, South Queensferry, UK).
Gene expression profiling and analysis
The Cancer Research UK Human Whole Genome-wide cDNA Array v1.0.0 (32K) (http://www.crukdmf.icr.ac.uk) was used as described earlier (Shepherd et al, 2008) and further information is given in Supplementary Information. Data were normalised and filtered to generate lists of genes with minimum 1.4-fold change in expression in at least three of five samples. The functional significance of differentially expressed genes was analysed using the ‘Database for Annotation Visualization and Integrated Discovery’ (DAVID) (http://david.abcc.ncifcrf.gov).
Amplified RNA was reverse transcribed using Superscript II (Invitrogen Ltd, Paisley, UK). Primer sequences and cycling conditions are provided in Supplementary Information. Following two rounds of PCR, products were resolved on a 3% agarose gel and detected under a UV transilluminator (BioDoc-It system; UVP, Cambridge, UK).
Immunofluorescence and immunohistochemistry
Paraffin-embedded sections were microwaved in antigen-unmasking solution (Vector Laboratories) for 30 min. Antibodies used are listed in Supplementary Table S1. Immunofluorescent labelling was carried out as described earlier (Alam et al, 2004). Immunohistochemical staining of TMA cores was detected using the Advance HRP kit and Liquid DAB+ substrate chromogen system (Dako, Ely, UK). Stained cores were reviewed by a pathologist. c-Cbl staining was scored on a scale of increasing intensity (1–3) and TEAD1 by increasing intensity (0–3) and as diffuse (in all tumour cells) or focal (localised to small groups of tumour cells).
Statistical analyses for survival
Survival was measured using the dates of death from any cause and death from prostate cancer. Patients were censored on their date of last follow-up if no death had been recorded. Lifetables were generated using the models of Kaplan and Meier. Differences between groups were examined using the log-rank test. Univariate and multivariate Cox regression analysis was performed using stepwise methods, a P-value of 0.05 was used as a threshold for inclusion in the model.
The RWPE1 cell line was derived from benign prostate and PC3 from a prostate cancer bone metastasis (both ATCC, LGC Standards, Teddington, UK). PC3 cells were cultured in F-12 Ham medium (Sigma-Aldrich) with 10% FCS (PAA Laboratories, Yeovil, UK) and L-glutamine (Invitrogen). RWPE1 cells were cultured in keratinocyte serum-free medium (KSFM) supplemented with bovine pituitary extract (25 mg), human recombinant epidermal growth factor (EGF) (2.5 μg) and L-glutamine (Invitrogen). Supplemented KSFM is referred to as bKSFM.
Pre-designed siRNA oligonucleotide duplexes for TEAD1 and c-Cbl were purchased from Qiagen (Crawley, UK) and ON-TARGETplus non-targeting siRNA no. 2 from Dharmacon (Thermo Scientific, Cramlington, UK). Mock controls were included. Reverse transfections were performed by mixing suspended cells with the siRNA oligonucleotides, Optimem I (Invitrogen) and Hiperfect (Qiagen), before plating. Final siRNA oligonucleotide concentrations were 5 nM (RWPE1) and 10 nM (PC3).
MTS proliferation assays
Reverse-transfected cells were plated into 96-well plates or 6 cm dishes. At each time point, proliferation was assessed using the Cell Titre 96 Aqueous One MTS assay (Promega, Southampton, UK). Plates were read using a BioTek ELx800 plate reader at 490 nm. Dishes were incubated for 72 h and protein extracted for knockdown verification. A one-way ANOVA with a Dunnett's multiple comparison test was performed in GraphPad Prism Version 5.01 (GraphPad Software Inc.).
3D culture in matrigel
Twenty-four hours after reverse transfection, RWPE1 cells were resuspended in bKSFM containing 2% Matrigel (BD Biosciences, Oxford, UK) and seeded into Matrigel-coated eight-well chamber slides (Nunc, VWR, Lutterworth, UK) (Debnath et al, 2003). Duplicate dishes were incubated for 120 h (corresponding to day 4 of the matrigel assay) before protein extraction. Acini formed by day 4 were scored and photographed under phase-contrast microscopy. The numbers of organised acini and disorganised aggregates were recorded for five fields of view. The number of disorganised aggregates was expressed as a percentage of the total number of structures and referred to as the percentage failure of acini formation.
Protein was extracted using mammalian protein extraction reagent (Pierce, Thermo Scientific, Cramlington, UK) supplemented with EDTA and protease inhibitor cocktail (Pierce). Lysates were resolved on a 4–12% Bis–Tris Nupage gel (Invitrogen). Antibodies were used as follows: TEAD1 (1 : 850), c-Cbl (1 : 1000), GAPDH (Chemicon, Chandlers Ford, UK) 1 : 10 000 and ECL peroxidase secondary antibody (GE Healthcare, Amersham, UK) (1 : 5000).
Expression profiling of microdissected basal and luminal cells identifies new markers for both populations
Basal and luminal cells were laser captured as illustrated in Figure 1A. Two rounds of RNA amplification yielded 24–38 μg of RNA with fragment sizes ⩽1500 bp. Microarray hybridisations were performed for each of the five basal and luminal samples, hybridising each against universal reference cDNA. Hierarchical clustering of the gene set (Figure 1A) showed a clear segregation of basal and luminal samples. A 1.4-fold cutoff relative to reference cDNA was applied for all differentially expressed genes, yielding basal and luminal lists of 112 and 267 genes, respectively. Basal/luminal or luminal/basal fold-change ratios were calculated to directly compare the two populations (Supplementary Tables S2a and S2b). K14 was overexpressed in the basal population, confirming positive cell separation. A number of differentially expressed genes were selected for verification of the microarray data by semiquantitative PCR (Figure 1B). Luminal expression of SNAP25 was confirmed in three out of three patients and basal expression of TEAD1 was confirmed in two out of three patients. Basal expression of integrin αV was confirmed in just one out of three patients and c-Cbl failed to generate any product. Owing to the varying success of the PCR, due, most likely, to the poor quality of the starting RNA, all further localisation confirmation was carried out using antibody staining.
To identify differences in key biological processes between basal and luminal cells, the web-based ontology program DAVID was used. This program categorises genes based on their biological or molecular function and assigns a P-value to each category. Filtering on a P-value less than or equal to 0.05 returned 14 basal cell categories and 23 luminal categories (Supplementary Table S3).
Immunofluorescence confirms the localisation of selected markers
Commercially available antibodies were used to confirm the protein localisation of a selection of novel markers in benign and malignant prostate tissue by immunofluorescence. The selection included genes identified as basal (ITGAV, TEAD1, c-Cbl and IL6) and luminal (SPRY1 and SNAP25). Double labelling with either K14 or K8 was used to confirm basal or luminal localisation of staining within benign prostate tissue. In agreement with the expression profiling data, TEAD1, c-Cbl and integrin αV were expressed in the basal layer and SNAP25 in the luminal layer (Figure 2A). We were unable to detect staining for IL6 or SPRY1. TEAD1 staining was nuclear in all cells within the basal layer, whereas c-Cbl was strongly cytoplasmic in the basal layer, with weak luminal staining. Integrin αV was found in subsets of cells within the basal layer, and clusters of integrin αV-positive cells were either K14 positive or negative. The SNAP25 antibody detected luminal cells, with a vesicular staining pattern. The same antibodies were also used on a small selection of prostate tumour samples. Although expression of SNAP25 and integrin αV could be detected in the tumours, integrin αV labelling was often weak, and results for SNAP25 were inconsistent between samples. As c-Cbl and TEAD1 staining was consistently high, these proteins were chosen for further study. c-Cbl was expressed in the cytoplasm of epithelial tumour cells, whereas TEAD1 was confined to the nuclei (Figure 2A).
TEAD1 and c-Cbl are independent prognostic factors of prostate cancer
To determine the clinical significance of TEAD1 and c-Cbl expression in prostate tumours, TMAs were stained for the two markers. Staining and patient data for positive cores are given in Table 1, with examples of typical staining patterns in Figure 2B. As shown by immunofluorescent staining, TEAD1 was localised to basal cell nuclei, whereas that for c-Cbl was cytoplasmic. In some strongly stained regions of the TMA, c-Cbl also appeared to be perinuclear (Figure 2B C2). The scoring systems are described in the Materials and Methods. Kaplan–Meier survival curves for TEAD1 and c-Cbl, representing deaths from all causes and prostate cancer-specific deaths, are shown in Figure 3. Staining distribution (focal or diffuse) and staining intensity for TEAD1 were considered as separate parameters. Diffuse staining was found to correlate with a poorer patient prognosis than focal (P=0.0092) (Figure 3A). However, this was not a significant factor in multivariate analysis because of a strong correlation with Gleason score, with diffuse TEAD1 staining found in predominately high Gleason cancers (Table 1). Staining intensity for TEAD1 showed a clear overlap in patient survival for groups 1 and 2, and patients with the highest intensity staining (group 3) had a highly significant reduced survival rate (P=0.0009) (Figure 3B). For both parameters, these differences are most striking in the prostate cancer-specific survival data.
c-Cbl staining was scored solely by intensity (scores 1–3). Survival data showed a clear divergence of intensity groups 1 and 2 at 7.5 years post-diagnosis, with an increased mortality rate for group 2 (Figure 3C). Group 3 patients had a particularly poor prognosis with a 50% survival rate of only 6 years compared with 14 years for group 1 (P=0.0106).
In Cox regression multivariate analysis, TEAD1 staining intensity scores were significantly associated with increased mortality, with a hazard ratio of 1.56 (95% CI 1.02–2.37; P=0.037) (Table 2).
Similarly, c-Cbl was found to be a highly significant independent predictor of survival (P=0.0005) with a hazard ratio of 1.99 (95% CI 1.35–2.92). One factor significant in the univariate analysis, although not in the multivariate analysis, was age.
Interestingly, of the 10 patients presenting with TEAD1 level 3, only four had level-3 c-Cbl, and there does not therefore appear to be a direct correlation between the two markers. This suggests that while high levels of either TEAD1 or c-Cbl are indicative of equally poor prognosis, they may identify somewhat different tumour types, supporting the observation that prostate cancer is a truly heterogeneous disease.
Knockdown of TEAD1 or c-Cbl reduces proliferation in PC3 cells
To investigate whether TEAD1 or c-Cbl has a role in proliferation, two well-established prostate cell lines were transfected with siRNA oligonucleotides targeting each gene. Knockdown was confirmed by western blotting and the effect on proliferation quantitated by MTS assays carried out over a 96-h time course (Figure 4A). Although the proliferation of RWPE1 cells was not affected by knockdown of either TEAD1 or c-Cbl, the proliferation of PC3 cells was significantly reduced. Data were normalised to proliferation of cells transfected with non-targeting siRNA. Normalisation to proliferation of mock-transfected cells yielded similar results.
Knockdown of TEAD1 or c-Cbl affects acinar formation in 3D culture
RWPE1 cells form spherically polarised acini, representative of the glandular structure of the prostate when cultured on matrigel (Webber et al, 1997). Cells were seeded in matrigel 24 h after transfection with TEAD1 or c-Cbl siRNA. After 4 days, acinar-like spherical structures with a well-defined border, often with less-dense cells in the centre, were formed (Figure 4Ba). Disorganised clusters were defined as aggregates of four or more cells that failed to form spherically polarised acini (Figure 4Bb and c). At day 4, the percentage failure of acini formation was calculated. The mean results of three independent experiments are shown in Figure 4B. TEAD1 knockdown significantly disrupted the number of spherically organised structures in comparison to the non-targeting control transfections, with an increased occurrence of disorganised clusters (T1_1=P0.006, T1_3=P0.009). Similarly, knockdown of c-Cbl also significantly reduced acini formation (cbl_8=P0.08, cbl_9=P0.003). These results are comparable with those of Kawano et al (2006), who found a 30% failure of acinar formation in response to the knockdown of the Wnt signalling pathway component Dickkopf-3 (DKK3).
Deregulation of proliferation and differentiation of prostate epithelial cells are predicted to underlie the development and progression of prostate cancers. As these processes are not well understood, it is not currently possible to predict patient outcome accurately. To identify key molecular factors involved in these processes, we have profiled gene expression associated with the basal and luminal epithelial cell layers. Genes expressed in basal cells are involved in maintaining a proliferative undifferentiated phenotype and promote cell survival. Therefore, we hypothesised that genes with their expression normally restricted to the basal layer play a key role in the progression of prostate malignancy. In this study, we determined the prognostic significance in prostate cancer of two novel markers of benign prostate basal cells.
Approaches to isolating different epithelial cell populations from the prostate have included lengthy processing and cell culture. This is expected to alter patterns of gene expression compared with cells in vivo. Therefore, we used laser-capture microdissection (Espina et al, 2007) combined with immunostaining for cellular recognition. As standard immunohistochemistry protocols lower RNA quality (Fend et al, 1999), we optimised a protocol to minimise the K14 staining procedure, enabling expression profiling of the microdissected cells. The 1.46-fold elevation of K14 expression levels in basal cells is modest considering that staining patterns show basal specificity. However, a lack of direct concordance between relative mRNA and protein levels in prostate tissue has been demonstrated earlier (Pascal et al, 2008).
Gene ontology analysis defined the functional categories upregulated in the two cellular populations. Luminal cells expressed negative regulators of the cell cycle, including the cyclin-dependent kinase inhibitors p21CIP1/WAF1 (CDKN1A) and p27KIP (CDKN1B), the latter having earlier been localised to prostate luminal cells (Harper et al, 1993; Fernandez et al, 1999), and the tumour suppressor genes NBL1 (Enomoto et al, 1994), NDRG1 (Daly-Burns et al, 2007) and PHB, which are downregulated in prostate cancer cells (Gamble et al, 2007). In keeping with the known interaction between the AR and calmodulin (Cifuentes et al, 2004), a further luminal functional category included several proteins related to calmodulin binding. Present in several functional categories was the luminal gene SNAP25. Although SNAP25 has not earlier been described in prostate, it has an established role in membrane trafficking and exocytosis for hormone secretion in other tissues, such as the pancreas (Sadoul et al, 1995).
The basal cell profile was consistent with a proliferative phenotype, with expression of CXCL1, NBS1 and RPA, all of which encode proteins shown earlier to promote proliferation (Chiang et al, 2003; Li et al, 2004; Givalos et al, 2007). The expression of αV integrin has earlier been described in metastatic prostate cancer (McCabe et al, 2007) but not in benign prostate cells, where it may have a role in adhesion to the basement membrane.
The protein localisation of two highly ranking genes in the basal list, protooncogene c-Cbl and the transcription factor TEAD1, confirmed them as basal cell markers not described earlier in prostate. Furthermore, an increased staining intensity for both c-Cbl and TEAD1 was observed in prostate cancer samples on a TMA. Significantly, multivariate analysis confirmed both as prognostic markers. Further study is now needed to investigate their possible clinical applications in the future. There is an urgent need for new predictive markers that distinguish the most aggressive prostate cancers at an early stage. Currently under investigation for its potential as a prognostic marker is the non-coding RNA PCA3 (Hessels et al, 2003). Although PCA3 has been proposed as an alternative to PSA for prostate cancer detection, its actual prognostic value is uncertain (van Gils et al, 2008). Likewise, although α-methylacyl CoA racemase (AMACR) staining is used diagnostically, it is not used to predict patient outcome (Luo et al, 2002). One recently discovered DNA biomarker that may provide prognostic information is the fusion between the gene TMPRSS2 and the ETS family genes such as ERG (Tomlins et al, 2005). In particular, duplication of the TMPRSS2–ERG fusion has been shown to identify aggressive tumours in patients whose prostate cancers had been assigned only intermediate Gleason scores (Attard et al, 2008). As staining intensities of both TEAD1 and c-Cbl also predict survival independently of Gleason score, they may prove also to be of significant prognostic value.
c-Cbl belongs to a family of E3 ubiquitin ligases (Swaminathan and Tsygankov, 2006). It binds to and ubiquitinates a range of receptor tyrosine kinases including EGFR (de Melker et al, 2001) and MET (hepatocyte growth factor receptor) (Peschard et al, 2001), both of which are localised to the basal layer and have reported roles in prostate proliferation and differentiation (Ibrahim et al, 1993; Pisters et al, 1995; Knudsen and Edlund, 2004; Schlomm et al, 2007). Receptor tyrosine kinases bound to c-Cbl are targeted to the endosomal compartment from where they are either trafficked to lysosomes for degradation or recycled back to the plasma membrane (Thien and Langdon, 2001). c-Cbl is, therefore, normally regarded as a negative regulator of proliferation. Interestingly, however, knockdown of c-Cbl in PC3 cells decreased proliferation. Importantly, c-Cbl also functions as an adaptor protein in signal transduction, for example downstream of integrins in which c-Cbl has been shown to interact with c-Src (Edick et al, 2007). Further investigation is needed to establish the role of c-Cbl in regulating prostate cancer cell proliferation.
The TEAD family of transcription factors, of which TEAD1 is the best characterised, regulate growth and differentiation in many tissues. This is exemplified by an important role for TEAD1 in embryonic development (Sawada et al, 2008; Zhang et al, 2008). TEAD1 binds several co-activators to stimulate the transcription of target genes (Gupta et al, 1997, 2001). Importantly, Yes-associated protein (YAP) is a TEAD1 co-activator localised to basal cell nuclei in normal prostate and overexpressed in prostate cancer (Zhao et al, 2007). TEAD1–YAP complexes promote the transcription of proliferative genes upon translocation of YAP to the nucleus, a process regulated by the Hippo pathway, which controls cell-contact inhibition of growth (Bandura and Edgar, 2008; Wu et al, 2008). As knockdown of TEAD1 led to a reduced proliferation in PC3 cells, it is possible that an increased expression of both TEAD1 and YAP could stimulate proliferation in prostate cancer.
The fact that knockdown of either TEAD1 or c-Cbl decreases the proliferation of PC3, but not RWPE1, is very interesting. This may reflect the different origins of the cell lines, RWPE1 having been immortalised from benign cells, whereas PC3 is of prostate cancer origin, representative of a highly aggressive, metastatic disease. As both TEAD1 and c-Cbl are highly expressed in aggressive prostate cancers, it could be possible that these aggressive cancers, and hence PC3, are dependent on these genes, directly or indirectly, for their proliferative capacity. Alternatively, RWPE1 proliferation may have been unaffected by TEAD1 or c-Cbl knockdown due to the immortalisation of this cell line with HPV18, which leads to the inactivation of p53 and Rb and, therefore, artificially high levels of proliferation. As a consequence of this, RWPE1 may have the ability to proliferate independently of TEAD1 or c-Cbl.
Although knockdown of TEAD1 or c-Cbl in RWPE1 did not affect proliferation in 2D culture, the ability of these cells to form acini in an established 3D assay (Bello-DeOcampo et al, 2001; Kawano et al, 2006) was compromised. These data suggest that TEAD1 and c-Cbl could have roles in regulating prostate epithelial cell differentiation and may have additional functions in epithelial morphogenesis, such as regulating adhesion to the basement membrane and associated signalling. Earlier studies have implicated a role for TEAD1 in the differentiation of keratinocytes (Takahashi et al, 1995) and skeletal muscle cells (Maeda et al, 2002), and a role for c-Cbl in maintaining an organised epithelium has been suggested earlier (Fournier et al, 2000). These preliminary functional studies clearly warrant further investigation into the roles of c-Cbl and TEAD1 in growth and differentiation in the prostate.
In summary, we have used a novel approach to identify two basal cell markers with high prognostic significance for prostate cancer. Interestingly, our preliminary functional study using well-established prostate cell lines has suggested a role for both genes in cellular proliferation and differentiation in the prostate, the two processes that are aberrantly regulated in cancer. Further study of TEAD1, c-Cbl and other basal markers may allow us to get an insight into the key molecular pathways that become disrupted in prostate malignancy.
Alam TN, O'Hare MJ, Laczko I, Freeman A, Al-Beidh F, Masters JR, Hudson DL (2004) Differential expression of CD44 during human prostate epithelial cell differentiation. J Histochem Cytochem 52: 1083–1090
Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS, Scardino P, Cuzick J, Cooper CS (2008) Duplication of the fusion of TMPRSS2 to ERG secquences identifies fatal human prostate cancer. Oncogene 27: 253–263
Bandura JL, Edgar BA (2008) Yorkie and Scalloped: partners in growth activation. Dev Cell 14: 315–316
Bello-DeOcampo D, Kleinman HK, Deocampo ND, Webber MM (2001) Laminin-1 and alpha6beta1 integrin regulate acinar morphogenesis of normal and malignant human prostate epithelial cells. Prostate 46: 142–153
Bonkhoff H, Remberger K (1996) Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 28: 98–106
Browne TJ, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA (2004) Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum Pathol 35: 1462–1468
Bui M, Reiter RE (1998) Stem cell genes in androgen-independent prostate cancer. Cancer Metastasis Rev 17: 391–399
Chiang YC, Teng SC, Su YN, Hsieh FJ, Wu KJ (2003) c-Myc directly regulates the transcription of the NBS1 gene involved in DNA double-strand break repair. J Biol Chem 278: 19286–19291
Cifuentes E, Mataraza JM, Yoshida BA, Menon M, Sacks DB, Barrack ER, Reddy GP (2004) Physical and functional interaction of androgen receptor with calmodulin in prostate cancer cells. Proc Natl Acad Sci USA 101: 464–469
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946–10951
Daly-Burns B, Alam TN, Mackay A, Clark J, Shepherd CJ, Rizzo S, Tatoud R, O'Hare MJ, Masters JR, Hudson DL (2007) A conditionally immortalized cell line model for the study of human prostatic epithelial cell differentiation. Differentiation 75: 35–48
de Melker AA, van der Horst G, Calafat J, Jansen H, Borst J (2001) c-Cbl ubiquitinates the EGF receptor at the plasma membrane and remains receptor associated throughout the endocytic route. J Cell Sci 114: 2167–2178
Debnath J, Muthuswamy SK, Brugge JS (2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256–268
Edick MJ, Tesfay L, Lamb LE, Knudsen BS, Miranti CK (2007) Inhibition of integrin-mediated crosstalk with epidermal growth factor receptor/Erk or Src signaling pathways in autophagic prostate epithelial cells induces caspase-independent death. Mol Biol Cell 18: 2481–2490
Enomoto H, Ozaki T, Takahashi E, Nomura N, Tabata S, Takahashi H, Ohnuma N, Tanabe M, Iwai J, Yoshida H, Matsunaga T, Sakiyama S (1994) Identification of human DAN gene, mapping to the putative neuroblastoma tumor suppressor locus. Oncogene 9: 2785–2791
Espina V, Heiby M, Pierobon M, Liotta LA (2007) Laser capture microdissection technology. Expert Rev Mol Diagn 7: 647–657
Fend F, Emmert-Buck MR, Chuaqui R, Cole K, Lee J, Liotta LA, Raffeld M (1999) Immuno-LCM: laser capture microdissection of immunostained frozen sections for mRNA analysis. Am J Pathol 154: 61–66
Fernandez PL, Arce Y, Farre X, Martinez A, Nadal A, Rey MJ, Peiro N, Campo E, Cardesa A (1999) Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression. J Pathol 187: 563–566
Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, Southgate C, Dowe A, Dearnaley D, Jhavar S, Eeles R, Feber A, Cooper CS (2004) Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 23: 5871–5879
Fournier TM, Lamorte L, Maroun CR, Lupher M, Band H, Langdon W, Park M (2000) Cbl-transforming variants trigger a cascade of molecular alterations that lead to epithelial mesenchymal conversion. Mol Biol Cell 11: 3397–3410
Gamble SC, Chotai D, Odontiadis M, Dart DA, Brooke GN, Powell SM, Reebye V, Varela-Carver A, Kawano Y, Waxman J, Bevan CL (2007) Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene 26: 1757–1768
Givalos N, Gakiopoulou H, Skliri M, Bousboukea K, Konstantinidou AE, Korkolopoulou P, Lelouda M, Kouraklis G, Patsouris E, Karatzas G (2007) Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer. Mod Pathol 20: 159–166
Gupta M, Kogut P, Davis FJ, Belaguli NS, Schwartz RJ, Gupta MP (2001) Physical interaction between the MADS box of serum response factor and the TEA/ATTS DNA-binding domain of transcription enhancer factor-1. J Biol Chem 276: 10413–10422
Gupta MP, Amin CS, Gupta M, Hay N, Zak R (1997) Transcription enhancer factor 1 interacts with a basic helix-loop-helix zipper protein, Max, for positive regulation of cardiac alpha-myosin heavy-chain gene expression. Mol Cell Biol 17: 3924–3936
Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805–816
Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L, Angel P, Mayer D (2005) Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res 11: 5146–5152
Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA (2003) DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 46: 271–272
Hudson DL, Guy AT, Fry P, O'Hare MJ, Watt FM, Masters JR (2001) Epithelial cell differentiation pathways in the human prostate: identification of intermediate phenotypes by keratin expression. J Histochem Cytochem 49: 271–278
Ibrahim GK, Kerns BJ, MacDonald JA, Ibrahim SN, Kinney RB, Humphrey PA, Robertson CN (1993) Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues. J Urol 149: 170–173
Kawano Y, Kitaoka M, Hamada Y, Walker MM, Waxman J, Kypta RM (2006) Regulation of prostate cell growth and morphogenesis by Dickkopf-3. Oncogene 25: 6528–6537
Klokk TI, Kilander A, Xi Z, Waehre H, Risberg B, Danielsen HE, Saatcioglu F (2007) Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Res 67: 5221–5230
Knudsen BS, Edlund M (2004) Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res 91: 31–67
Li A, Varney M, Singh R (2004) Constitutive expression of growth regulated oncogene (gro) in human colon carcinoma cells with different metastatic potential and its role in regulating their metastatic phenotype. Clin Exp Metastasis 21: 571–579
Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM (2002) α-Methylacyl-CoA Racemase. A new molecular marker for prostate cancer. Cancer Res 62: 2220–2226
Maeda T, Chapman DL, Stewart AF (2002) Mammalian vestigial-like 2, a cofactor of TEF-1 and MEF2 transcription factors that promotes skeletal muscle differentiation. J Biol Chem 277: 48889–48898
McCabe NP, De S, Vasanji A, Brainard J, Byzova TV (2007) Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene 26: 6238–6243
McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940–6944
Pascal LE, True LD, Campbell DS, Deutsch EW, Risk M, Coleman IM, Eichner LJ, Nelson PS, Liu AY (2008) Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genomics 9: 246
Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG (2007) Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 67: 6796–6805
Peschard P, Fournier TM, Lamorte L, Naujokas MA, Band H, Langdon WY, Park M (2001) Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell 8: 995–1004
Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LW (1995) c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 154: 293–298
Sadoul K, Lang J, Montecucco C, Weller U, Regazzi R, Catsicas S, Wollheim CB, Halban PA (1995) SNAP-25 is expressed in islets of Langerhans and is involved in insulin release. J Cell Biol 128: 1019–1028
Sawada A, Kiyonari H, Ukita K, Nishioka N, Imuta Y, Sasaki H (2008) Redundant roles of Tead1 and Tead2 in notochord development and the regulation of cell proliferation and survival. Mol Cell Biol 28: 3177–3189
Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, Walz J, Chun FH, Haese A, Kollermann J, Graefen M, Huland H, Sauter G, Simon R, Erbersdobler A (2007) Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 13: 6579–6584
Shepherd CJ, Rizzo S, Ledaki I, Davies M, Brewer D, Attard G, de Bono J, Hudson DL (2008) Expression profiling of CD133(+) and CD133(−) epithelial cells from human prostate. Prostate 68: 1007–1024
Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, Dhar S, Majumder P, McKeon F, Kantoff PW, Sellers WR, Loda M (2005) p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci USA 102: 11355–11360
Swaminathan G, Tsygankov AY (2006) The Cbl family proteins: ring leaders in regulation of cell signaling. J Cell Physiol 209: 21–43
Takahashi H, Kobayashi H, Matsuo S, Iizuka H (1995) Repression of involucrin gene expression by transcriptional enhancer factor 1 (TEF-1). Arch Dermatol Res 287: 740–746
Thien CB, Langdon WY (2001) Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2: 294–307
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Verambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644–648
van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, Witjes JA, Jansesn CF, Mulders PF, Rittenhouse HG, Schalken JA (2008) Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 68: 1215–1222
Wang H, McKnight NC, Zhang T, Lu ML, Balk SP, Yuan X (2007) SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res 67: 528–536
Webber MM, Bello D, Kleinman HK, Hoffman MP (1997) Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis 18: 1225–1231
Wu S, Liu Y, Zheng Y, Dong J, Pan D (2008) The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. Dev Cell 14: 388–398
Zhang L, Ren F, Zhang Q, Chen Y, Wang B, Jiang J (2008) The TEAD/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control. Dev Cell 14: 377–387
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, Halder G, Lai ZC, Guan KL (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21: 2747–2761
We thank Melissa Davies, Nadine Quatan and Nening Dennis for tissue collection, and Farah Al Beidh and Brenda Summersgill for laboratory assistance. This work was supported by the Bob Champion Cancer Trust (DLH, CJS and SR), Prostate Cancer Research Foundation (DLH) and Medical Research Council (JFK). MDG is funded by Cancer Research UK (CRUK) Grant C309/A8274 and The Institute of Cancer Research.
About this article
Cite this article
Knight, J., Shepherd, C., Rizzo, S. et al. TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer. Br J Cancer 99, 1849–1858 (2008). https://doi.org/10.1038/sj.bjc.6604774
- prostate cancer
- laser-capture microdissection
E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK–CBL–CIN85 axis
YAP1 plays a key role of the conversion of normal fibroblasts into cancer-associated fibroblasts that contribute to prostate cancer progression
Journal of Experimental & Clinical Cancer Research (2020)
Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer
BMC Cancer (2020)
TEAD4 overexpression promotes epithelial-mesenchymal transition and associates with aggressiveness and adverse prognosis in head neck squamous cell carcinoma
Cancer Cell International (2018)
Hippo pathway affects survival of cancer patients: extensive analysis of TCGA data and review of literature
Scientific Reports (2018)